Prospective evaluation of the prevalence of factor V Leiden mutation in portal or hepatic vein thrombosis.
Denninger
M H
MH
Helley
D
D
Valla
D
D
Guillin
M C
MC
D016736:Antiphospholipid Syndrome / Q000150:complications / Q000453:epidemiology; D006502:Budd-Chiari Syndrome / Q000097:blood / Q000453:epidemiology / Q000209:etiology / Q000235:genetics*; D015897:Comorbidity; D004198:Disease Susceptibility; D004789:Enzyme Activation; D005165:Factor V / Q000032:analysis* / Q000235:genetics; D005260:Female; D005602:France / Q000453:epidemiology; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D008297:Male; D009196:Myeloproliferative Disorders / Q000150:complications / Q000453:epidemiology; D011169:Portal Vein; D015995:Prevalence; D011446:Prospective Studies; D011486:Protein C / Q000378:metabolism; D012307:Risk Factors; D019851:Thrombophilia / Q000453:epidemiology* / Q000209:etiology / Q000235:genetics; D013927:Thrombosis / Q000097:blood / Q000453:epidemiology / Q000209:etiology / Q000235:genetics*
D011486:Protein C; C095381:factor V Leiden; D005165:Factor V